Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.
Antoni Ribas(University of California, Los Angeles), Adil Daud(University of California, San Francisco), Jennifer H. Yearley(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hassane M. Zarour(University of Pittsburgh), Erin Murphy(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jeffrey S. Weber(NYU Langone Health), Michael Nebozhyn(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jedd D. Wolchok(Cornell University), Andrey Loboda(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jared Lunceford(Merck & Co., Inc., Rahway, NJ, USA (United States)), Richard Kefford(Broad Institute), Andrew Albright(Merck & Co., Inc., Rahway, NJ, USA (United States)), F. Stephen Hodi(Harvard University), Anthony M. Joshua(St Vincent's Hospital Sydney), Terri McClanahan(Merck & Co., Inc., Rahway, NJ, USA (United States)), Caroline Robert(Institut Gustave Roussy), Wen‐Jen Hwu(The University of Texas MD Anderson Cancer Center), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Soonmo Peter Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mark Ayers(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 200
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k